A programmable arthritis-specific receptor for guided articular cartilage regenerative medicine

• Published in: bioRxiv
• Main Authors: Walton, Bonnie L, Shattuck-Brandt, Rebecca, Hamann, Catherine A, Tung, Victoria W, Colazo, Juan M, Brand, David D, Hasty, Karen A, Duvall, Craig L, Brunger, Jonathan M
• Format: Journal Article Paper
• Language: English
• Published: United States Cold Spring Harbor Laboratory Press 15.02.2024
• Subjects: Arthritis; Cartilage; Cartilage (articular); Cartilage diseases; Cell activation; Cell culture; Chondrocytes; Collagen (type II); Drug delivery; Fibers; Gene expression; Inflammation; Interleukin 1 receptor antagonist; Interleukin 1 receptors; Mesenchymal stem cells; NF-κB protein; Osteoarthritis; Polymerase chain reaction; Regenerative medicine; Stromal cells; Transgenes
• DOI: 10.1101/2024.01.31.578281

Investigational cell therapies have been developed as disease-modifying agents for the treatment of osteoarthritis (OA), including those that inducibly respond to inflammatory factors driving OA progression. However, dysregulated inflammatory cascades do not specifically signify the presence of OA. Here, we deploy a synthetic receptor platform that regulates cell behaviors in an arthritis-specific fashion to confine transgene expression to sites characterized by cartilage degeneration. An scFv specific for type II collagen (CII) was used to produce a synthetic Notch (synNotch) receptor that enables "CII-synNotch" mesenchymal stromal cells (MSCs) to recognize CII fibers exposed in damaged cartilage. Engineered cell activation by both CII-treated culture surfaces and on primary tissue samples was measured via inducible reporter transgene expression. TGFβ3-expressing cells were assessed for cartilage anabolic gene expression via qRT-PCR. In a co-culture with CII-synNotch MSCs engineered to express IL-1Ra, ATDC5 chondrocytes were stimulated with IL-1α, and inflammatory responses of ATDC5s were profiled via qRT-PCR and an NF-κB reporter assay. CII-synNotch MSCs are highly responsive to CII, displaying activation ranges over 40-fold in response to physiologic CII inputs. CII-synNotch cells exhibit the capacity to distinguish between healthy and damaged cartilage tissue and constrain transgene expression to regions of exposed CII fibers. Receptor-regulated TGFβ3 expression resulted in upregulation of and in MSCs, and inducible IL-1Ra expression by engineered CII-synNotch MSCs reduced pro-inflammatory gene expression in chondrocytes. This work demonstrates proof-of-concept that the synNotch platform guides MSCs for spatially regulated, disease-dependent delivery of OA-relevant biologic drugs.